Compliance with reporting clinical trial results varies across research fields and types of sponsors. In rheumatology, most industry-funded trials of biologic agents are currently reported promptly. Optimizing clinical research will nevertheless require steps beyond deposition of summary results, including making raw data and protocols available, and assuring independence of the research agenda.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
US Food and Drug Administration. Food and Drug Administration Amendments Act of 2007. Public Law 110–85 [online], (2007).
Anderson, M. L. et al. Compliance with results reporting at ClinicalTrials.gov. N. Engl. J. Med. 372, 1031–1039 (2015).
Prayle, A. P., Hurley, M. N. & Smyth, A. R. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ 344, d7373 (2012).
Law, M. R., Kawasumi, Y. & Morgan, S. G. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. Health Aff. (Millwood) 30, 2338–2345 (2011).
Saito, H. & Gill, C. J. How frequently do the results from completed US clinical trials enter the public domain?—A statistical analysis of the ClinicalTrials.gov database. PLoS ONE 9, e101826 (2014).
Ioannidis, J. P. & Karassa, F. B. The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. BMJ 341, c4875 (2010).
Ioannidis, J. P., Karassa, F. B., Druyts, E., Thorlund, K. & Mills, E. J. Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales. Nat. Rev. Rheumatol. 9, 665–673 (2013).
Khan, N. A., Lombeida, J. I., Singh, M., Spencer, H. J. & Torralba, K. D. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. Arthritis Rheum. 64, 2059–2067 (2012).
Goodman, S. N. Clinical trial data sharing: what do we do now? Ann. Intern. Med. 162, 308–309 (2015).
Flacco, M. E. et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J. Clin. Epidemiol. http://dx.doi.org/10.1016/j.jclinepi.2014.12.016 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Table 1
Update as of 27 March 2015 on RCTs of anti-TNF agents in immune-mediated diseases that were registered by January 20, 2013 in ClinicalTrials.gov but had not been published by that time.* (DOCX 34 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Karassa, F., Ioannidis, J. A transparent future for clinical trial reporting. Nat Rev Rheumatol 11, 324–326 (2015). https://doi.org/10.1038/nrrheum.2015.65
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.65
This article is cited by
-
Diagnosing the declining industry sponsorship in clinical research
Scientometrics (2024)